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Abstract Precision medicine aims to improve patient care
by adjusting medication to each patient’s individual needs.
Age-related macular degeneration (AMD) is a heteroge-
neous eye disease in which several pathways are involved,
and the risk factors driving the disease differ per patient.
As a consequence, precision medicine holds promise for
improved management of this disease, which is nowadays a
main cause of vision loss in the elderly. In this review, we
provide an overview of the studies that have evaluated the
use of molecular biomarkers to predict response to treat-
ment in AMD. We predominantly focus on genetic
biomarkers, but also include studies that examined circu-
lating or eye fluid biomarkers in treatment response. This
involves studies on treatment response to dietary supple-
ments, response to anti-vascular endothelial growth factor,
and response to complement inhibitors. In addition, we
highlight promising new therapies that have been or are
currently being tested in clinical trials and discuss the
molecular studies that can help identify the most suit-
able patients for these upcoming therapeutic approaches.
Key Points
Current work on genetic and molecular biomarkers
for treatment response in age-related macular
degeneration (AMD) is still exploratory, and
precision medicine for AMD is not yet ready for
implementation in the clinic.
Several genetic and molecular biomarkers that
associate with response to anti- vascular endothelial
growth factor therapy have been identified, but these
associations have not been consistently replicated.
Studies on complement system biomarkers may be
useful to identify patients for complement-inhibiting
therapies that are currently under development.
1 Introduction
Precision medicine aims to improve healthcare through
individualized selection of treatment options, taking into
account each patient’s characteristics and individual needs.
Biomarkers defining individual patient characteristics can
be used in a clinical setting to define individualized
screening strategies, recommend personalized preventions,
select the best therapy for individual patients, tailor the
dosing of medication, and can help avoid patients being
given unnecessary treatments that they will not benefit
from or might even be harmful. The field of precision
medicine has moved forward rapidly in the last few dec-
ades thanks to the identification of genetic markers that
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predict response to treatment in many different diseases
[1]. Genetic screening prior to treatment is now increas-
ingly being implemented in the healthcare system [2–4]. A
prime example is the oncology field, where, for instance,
genetic variants in the DPYD gene are highly recom-
mended to be screened to avoid toxicity from fluoropy-
rimidine drugs [5]. Other examples include the anti-
coagulant warfarin, for which genotype-guided prescrip-
tion has been established to improve safety and effective-
ness, and to reduce healthcare costs [6–8]. Besides genetic
markers, other biomarkers such as metabolites are also
being explored for clinical utility in precision medicine [9].
In the field of ophthalmology, the potential of precision
medicine is actively being investigated. The focus of this
review is age-related macular degeneration (AMD), the
most common cause of blindness in the elderly in the
Western world, and the third most common cause of severe
visual impairment worldwide [10, 11]. The increased
ageing of the population is boosting the number of affected
individuals, which is expected to reach 196 million by
2020, therefore posing a major and rising burden on
healthcare [12]. AMD is a progressive disease that affects
the macula, which is located in the center of the retina, and
is responsible for central vision, color vision and sharp
vision. In early stages, AMD is characterized by the
occurrence of drusen, which are deposits of extracellular
debris that accumulate underneath the retinal pigment
epithelium (RPE), the cell layer supporting the neurosen-
sory retina [13]. During the course of the disease, drusen
increase in number and size, and AMD can progress into
advanced stages in which vision loss occurs. These
advanced stages can be divided in two types: geographic
atrophy (GA) and choroidal neovascularization (CNV). GA
is characterized by atrophy of the retina, resulting from
gradual loss of photoreceptors, RPE cells and the chorio-
capillaris [14]. CNV, also referred to as neovascular AMD
(nvAMD), involves the abnormal growth of blood vessels
from the choriocapillaris invading the retina, with subse-
quent leakage and bleeding, and provokes a vision-threat-
ening scar in the macula. The prevalence of both advanced
types is similar, and both types of the disease cause visual
loss [12]; however, nvAMD accounts for most of the visual
acuity loss caused by AMD [15].
AMD is a complex heterogeneous disease in which
genetic factors as well as environmental factors contribute
to disease risk. Genetic factors play a major role in the
disease etiology, explaining up to 71% of the disease
variation [16]. The first single-nucleotide polymorphisms
(SNPs) found to be associated with AMD were rs1061170
in CFH and rs10490924 in ARMS2 [17, 18]. In a recent
genome-wide association study (GWAS), 52 independent
genetic variants across 34 loci were identified to influence
AMD disease risk [19]. These genetic associations have
implicated the complement system, lipid metabolism,
extracellular matrix remodeling and angiogenesis in the
disease process [19]. Age is the most important demo-
graphic risk factor for AMD development, and other fac-
tors that have consistently been described to influence the
disease risk are cigarette smoking, previous cataract sur-
gery and family history of AMD [20].
Currently, only advanced nvAMD can be treated, by
targeting vascular endothelial growth factor (VEGF). For
GA, although several therapies are actively being devel-
oped, no established treatment is available to date. Also,
progression of the disease cannot be halted, but it can be
slowed down with the use of nutritional supplements.
Due to the heterogeneity in the AMD patient population,
it is plausible that the effect of therapeutic interventions
depends on the biological drivers of disease in each indi-
vidual patient. In essence, the patient’s genetic blueprint, in
addition to demographic and lifestyle factors, is likely to
influence how a patient responds to treatment. Conse-
quently, the identification of biomarkers that can predict
response to therapy in AMD could be used to improve
AMD patient care, by tailoring medication to each patient’s
individual needs.
In this review, we aim to provide an overview of the
current literature investigating the association of
biomarkers with response to supplements and anti-VEGF
therapy, as well as to describe new therapeutic approaches
undergoing clinical trials and the potential use of
biomarkers for patient selection.
2 Current Therapeutic Interventions for Age-
Related Macular Degeneration Management
2.1 Dietary Supplements for Slowing Disease
Progression
Dietary supplementation with vitamins and zinc is proven
to reduce the risk of progression to advanced AMD. These
supplements act against oxidative stress, which is thought
to be one of the drivers of AMD pathogenesis [21, 22].
Oxidative stress refers to a disturbance in the balance
between the production of reactive oxygen species and
antioxidant defenses. The retina is highly susceptible to
oxidative stress due to sunlight exposure, high oxygen
consumption and high concentration of polyunsaturated
fatty acids. Moreover, oxidative stress increases with age
and is associated with smoking, another AMD risk factor
[22]. The notion that oxidative stress may play an impor-
tant role in AMD development and progression led to the
development of the Age-Related Eye Disease Study
(AREDS) clinical trial that evaluated the effect of high
doses of vitamin C, vitamin E, beta-carotene and zinc on
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AMD progression. In 2001, the AREDS trial concluded
that patients with intermediate AMD in at least one eye
receiving this formulation reduced their risk of progression
to advanced AMD by 25% at 5 years [23]. An AREDS 2
supplementation trial followed in 2013, describing an
improved formula with lutein and zeaxanthin substituting
beta-carotene. This formula showed the same effects, but is
preferred as beta-carotene conferred risk for lung cancer in
former smokers [24]. Clinicians have rapidly adopted the
AREDS recommendations, and the oral use of antioxidants
combined with zinc is currently prescribed for intermediate
or unilateral advanced AMD.
AMD-associated variants have been found to influence
AMD progression, and for several years, there have been
investigations into whether specific genotypes interact with
the AREDS supplementation, affecting progression rates
[25]. These studies sparked an intense debate in the field as
different research groups arrived at different conclusions.
In 2008, Klein et al. suggested that response to AREDS
supplements could be related to the CFH rs1061170
genotype [26]. The study evaluated 876 AREDS patients
and found that for carriers of the CC genotype, dietary
supplementation would have a smaller effect, possibly
related to zinc consumption, but would still be beneficial.
No interaction was found for the ARMS2 rs10490924 SNP.
In 2013, a second study that included 995 AREDS partic-
ipants was published by Awh et al., also proposing a
genotypic interaction [27] and suggesting that improved
outcomes could be obtained after genotype selection. The
authors described a deleterious interaction between CFH
risk alleles (rs412852 and rs3766405) and supplementation
with zinc, in which carriers of CFH risk alleles would
progress to advanced AMD faster when taking zinc. Also,
the authors claimed that individuals homozygous for the
CFH and ARMS2 risk alleles would not benefit from the
AREDS formula. After these results, the AREDS Research
Group attempted replication in a larger AREDS cohort of
1237 AMD patients, but did not identify any interaction,
and concluded that reduction in the risk of AMD pro-
gression after supplementation was seen in all genotype
groups [28]. This study was followed by a series of con-
tradictory results [29–31] and intense argumentation
[32–34]. In a recent report, independent statistical research
groups analyzed the data from the AREDS Research Group
and from Awh and colleagues. Errors in the Awh et al.
2013 study were noted, and no interaction was reported
between the CFH and ARMS2 SNPs and treatment
response after correction for multiple testing. Therefore, it
was concluded that AMD patients should be offered dietary
supplementation regardless of genotype [35]. The most
recent study performed multiple statistical analyses on an
extended AREDS dataset of 802 individuals and suggested
that the response to AREDS formulation treatment varies
substantially among individuals, based on CFH and
ARMS2 genotypes. This study therefore concludes that the
use of the AREDS formulation should be based on patient-
specific genotypes [36].
2.2 Anti-VEGF Antibodies for Choroidal
Neovascularization Treatment
The gold-standard treatment for nvAMD consists of
intravitreal injections of anti-VEGF antibodies. VEGFA is
the master regulator of angiogenesis and leads to prolifer-
ation, migration and survival of vascular endothelial cells,
as well as to vascular permeability [37, 38]. In the AMD
disease process, hypoxia, oxidative stress and activation of
the complement system promote VEGFA secretion by the
RPE, which will eventually lead to abnormal CNV for-
mation [39–41]. Anti-VEGF antibodies block VEGFA
binding to its receptors and thus inhibit its angiogenic
effects.
Anti-VEGF antibodies for nvAMD treatment include
ranibizumab (Lucentis; Novartis, Basel, Switzerland, and
Genentech Inc., South San Francisco, USA), bevacizumab
(Avastin, Genentech, South San Francisco, USA), and
aflibercept (EYLEA, Regeneron Pharmaceutical Inc., Tar-
rytown, USA). Bevacizumab has been approved by the
Food and Drug Administration (FDA) for the treatment of
several cancer types; however, it is administered off label
for the treatment of nvAMD. The CATT and IVAN clinical
trials demonstrated similar outcomes after bevacizumab
treatment compared to ranibizumab [42–45]. The admin-
istration of these agents usually consists of a loading dose
of three monthly injections followed-up with a variable
treatment regimen.
The use of anti-VEGF drugs to treat nvAMD has sig-
nificantly changed the prognosis of the disease and has led
to significant improvements in visual acuity. Nevertheless,
a more detailed analysis of individual patient outcomes
shows that not all patients benefit equally from the therapy.
Vision remains stable or improves in approximately 80%
of the patients, but approximately 20% of treated patients
continue to lose vision despite treatment [46, 47]. Along
the same line, anatomical changes in the retina after
treatment, reflecting fluid clearance, are also variable
among patients [42].
Understanding the reasons underlying this variability in
treatment outcome can help improve treatment strategies,
would allow early identification of poor responders, and
would enable individual treatment optimization. Clinical
and epidemiological factors that have repeatedly been
associated with worse treatment outcome include baseline
parameters such as older age, larger CNV lesion, larger
retinal tissue thickness and lower visual acuity [48]. These
factors are highly correlated and indicative of longer
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disease duration, highlighting the importance of initiating
treatment in an early phase. Nevertheless, these factors
cannot fully explain the wide range in treatment outcomes
[49]. Due to the highly heritable nature of AMD, it has
been hypothesized that genetic factors may influence
treatment outcome. Genetic markers are independent of
disease duration and therefore may explain treatment out-
come variability.
Since the first publication in 2007 [50], a vast number of
studies have investigated associations of genetic variants
with anti-VEGF treatment outcome in nvAMD. We
reviewed the pharmacogenetic studies published to date
and provide a detailed overview of their study designs and
conclusions in Table 1. Despite the large body of literature
on this topic, with over 50 studies published, solid con-
clusions cannot be drawn. This is due to conflicting results
and a high heterogeneity in study designs, which makes
comparisons between studies challenging. Studies may
involve ranibizumab treatment, bevacizumab treatment or
both. Moreover, the definition of treatment response is
highly variable: change in visual acuity, change in total
retinal thickness, CNV recurrence or number of injections
are some of the variables used to measure treatment out-
come. These variables are analyzed in a continuous or in a
categorical manner, in which responders are compared to
non-responders based on an arbitrary definition of
response. Additionally, the studies evaluate response after
the loading dose of three monthly injections or longer and
may therefore involve different treatment protocols. Also,
correction for multiple testing is not applied in all studies,
and the majority of studies do not provide a statistical
power calculation.
At the onset of the field of pharmacogenetics in AMD, a
natural target to explore was the main genetic variant
associated with AMD: SNP rs1061170 in the CFH gene.
Indeed, most of the studies have investigated this SNP;
however conflicting results have been reported. Several
studies have reported an association of this genetic variant
with response to anti-VEGF treatment [50–63]; in all
instances, the AMD-risk-conferring allele (C) led to a
worse outcome after therapy. However, others have not
identified any association [64–78]. Three different meta-
analyses have been carried out, all showing an association
of rs1061170 with treatment response with a moderate
level of significance [79–81]. The most recent and com-
prehensive study included a total of 2963 individuals from
14 different studies and showed that patients homozygous
for the AMD low-risk allele (T) were more likely to have a
better outcome compared to patients homozygous for the
AMD high-risk allele (C) [odds ratio (OR) = 1.932, 95%
confidence interval (CI) 1.125–3.173, P = 0.017] [81].
Notably, the two studies based on the IVAN and CATT
clinical trials did not find any association for this variant,
nor for any other variant investigated, despite their large
sample sizes (n = 834 and n = 509, respectively) [71, 72].
The SNPs in ARMS2/HTRA1 (rs10490924 and
rs11200638, which are in high linkage disequilibrium) [82]
have also been widely evaluated for association with treat-
ment outcome. A similar scenario emerged for these SNPs,
where several studies reported an association in which the
AMD-risk allele leads to worse response
[59, 64, 67, 69, 70, 75, 77, 83], while others do not report an
association [50, 52, 59, 60, 62, 65, 68, 71–73, 78, 84–87]. As
an exception, Kang and colleagues described that carriers of
the AMD-risk allele in rs10490924 needed fewer beva-
cizumab injections after the loading dose [57]. A meta-
analysis including 2389 cases from 12 studies showed that
patients homozygous for the AMD low-risk allele in ARMS2
rs10490924 (GG) have a higher chance of responding better
to treatment compared to patients heterozygous (TG) or
homozygous (TT) for the AMD high-risk allele (OR = 1.34,
95% CI 1.01–1.77, P = 0.039), although no significant dif-
ference was found on the allele level. Also, no differences
were found when the analysis was limited to patients of
European descent [88]. Another meta-analysis of 1570 cases
from five studies showed no association for the SNP
rs11200638 [89]. Most study designs evaluated treatment
outcome after 3–12 months of treatment, but a recent study
evaluated the effect of genetic variants after 4 years of anti-
VEGF treatment. This study by Valverde-Megı´as et al.
examined the rs1061170CFH and rs10490924ARMS2SNPs
and reported that patients homozygous for the AMD-risk
allele of the ARMS2 SNP required more injections over this
long-term follow-up period [77].
Due to the nature of anti-VEGF therapy, the VEGFA gene
and the KDR gene, encoding the main receptor for VEGFA,
were also considered candidates to be involved in anti-VEGF
treatment response. Most of the SNPs investigated in these
genes have recently been evaluated in a meta-analysis. After
evaluation of nine SNPs (rs699947, rs699946, rs833069,
rs833061, rs2146323, rs1413711, rs2010963 and rs1570360
in VEGFA, and rs2071559 in KDR), anti-VEGF treatment
was found to be more effective in patients homozygous for
the VEGFA rs833061 minor allele C, compared to the
remaining AMD patients (OR = 2.362, 95% CI 1.41–3.95,
P = 0.001). This analysis was, however, limited in sample
size, including only 444 AMD patients from three indepen-
dent studies [90]. An SNP (rs2070296) in the neuropilin-1
(NRP1) gene, encoding the co-receptor for VEGF, has been
associated with worse response to treatment in one study
[91], but this SNP has not yet been evaluated in independent
cohorts. Other reported associations with treatment response
include the APOE e4 allele [92, 93], IL8 rs4073 [59, 73, 94],
and PEDF rs1136287 [52], which have been analyzed in
only a limited number of studies and warrant replication
analyses.
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The aforementioned variants have been examined in
candidate gene/variant studies because of their known role
in AMD or the neovascularization process. In contrast,
GWASs examine genetic variation across the whole gen-
ome in a hypothesis-free approach. Three GWASs for anti-
VEGF treatment response have been published to date
[83, 95, 96]. The first study, by Francis, involved only 65
AMD patients. When evaluating only candidate genes, an
association with visual acuity outcome was reported for
CFH rs1065489, and an association with change in macular
thickness was reported for C3 rs2230205 [95]. In the sec-
ond study, Riaz and colleagues included a total of 673
AMD patients and, after replication in an independent
cohort, described rs4910623 located in the olfactory
receptor gene OR52B4 as a new variant associated with
worse treatment outcome [96]. The last study by Yama-
shiro et al. analyzed 461 AMD patients collected in a
prospective study design, and in a discovery and replication
setting. The discovery GWAS phase in 256 patients did not
identify any genome-wide associations, and suggestive
associations could not be replicated. In a candidate SNP
analysis that included nine variants, ARMS2 rs10490924 G
was associated with additional treatment requirement after
the loading dose [83].
In addition to the pharmacogenetic studies, other
biomarkers have also been described to be associated with
anti-VEGF treatment response in nvAMD. In aqueous
humor, VEGF and interleukin-6 (IL-6) levels have been
measured prior to treatment, and they seem to be indicative
of the outcome. Lai and colleagues reported that baseline
aqueous VEGF levels associated with persistent angio-
graphic leakage after 3 months of bevacizumab therapy
[97]. In another study, by Chalam and colleagues, corre-
lations of VEGF and IL-6 levels with change in central
subfield macular thickness after three monthly injections of
bevacizumab treatment were described, with the correla-
tion of IL-6 levels being the strongest [98].
Studies in plasma and serum have also suggested
potential systemic biomarkers. Kepez Yildiz et al. descri-
bed higher levels of plasma IL-6 in good responders
compared to non-responders [99]. Nassar and colleagues
evaluated 16 inflammatory cytokines and found that high
IL-17 and tumor necrosis factor-a (TNF-a) serum levels
were associated with favorable response to anti-VEGF
therapy [100]. Lechner et al. described that plasma com-
plement component (C3a) levels were elevated in partial
responders compared to complete responders; no differ-
ences were found for C4a and C5a levels [101]. Addi-
tionally, Kubicka-Trza˛ska and colleagues analyzed serum
anti-retinal antibodies and reported that a decrease in anti-
retinal antibodies levels after bevacizumab treatment cor-
related with functional and anatomical response [102].
3 Therapies in Clinical Trials
3.1 Complement-Inhibiting Therapies
Anti-VEGF treatment is currently only indicated for
nvAMD, which affects only half of the advanced AMD
patients. For the other half, who suffer from GA, no
treatment is available yet. Current research and develop-
ment efforts are heavily focused on this category of
patients, and genetic and physiological associations are
used to identify targets for therapy. Based on this, a prime
candidate target in AMD is the complement system, an
essential component of the immune system. The comple-
ment system consists of an intricate proteolytic cascade
that leads to inflammation, opsonization and targeted
cytolysis through the formation of the membrane attack
complex (MAC) (Fig. 1) [103]. Over-activation of the
complement system, particularly of the alternative path-
way, has been described to be associated with AMD [104].
Consequently, several therapies aiming to inhibit comple-
ment activity are being developed. These therapies aim to
slow down disease progression and to prevent the devel-
opment of GA, but may also be useful for nvAMD patients
in combination with anti-VEGF drugs.
Complement-inhibiting therapies that have gone through
clinical trials include APL-2, lampalizumab, eculizumab,
tesidolumab, CLG561, Zimura and AAVCAGsCD59 (also
known as HMR59) (Fig. 1a). These drugs inhibit the
complement system at different levels of the proteolytic
cascade.
APL-2 (Apellis Pharmaceuticals, Crestwood, USA), a
reformulated version of POT-4, is a cyclic peptide inhibitor
of complement component 3 (C3). This drug is currently
being tested in a phase II clinical trial (https://clinicaltrials.
gov, NCT02503332). According to Apellis Pharmaceuti-
cals (http://www.apellis.com), this clinical trial has already
resulted in a significant reduction in the rate of geographic
lesion growth over 12 months. Lampalizumab (Genentech
Inc., South San Francisco, CA) is an antigen-binding
fragment of a humanized monoclonal antibody that targets
complement factor D (FD). The phase II clinical trial for
Lampalizumab (MAHALO) has been completed, and
yielded promising results with a 20% reduction in atrophy
area progression at month 18 for the monthly treated group
compared to placebo [105]. Lampalizumab is currently
being evaluated in two phase III clinical trials (SPECTRI
and CHROMA, NCT02247531 and NCT02247479,
respectively). Recently, Genentech revealed in a press
release that SPECTRI did not meet its primary endpoint of
reducing mean change in GA lesion area, and that they are
expecting the results of CHROMA to be evaluated in
November 2017. Eculizumab (Soliris, Alexion
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Pharmaceuticals, New Haven, USA) is a humanized
monoclonal antibody targeting complement 5 (C5). Eculi-
zumab has been approved for the treatment of paroxysmal
nocturnal hemoglobinuria. In a phase II clinical trial in
AMD (COMPLETE, NCT00935883), systemically
administered eculizumab was well-tolerated; however, it
did not decrease the growth rate of GA significantly [106].
Another drug targeting C5 is Zimura (Ophtotech, USA), a
chemically synthesized aptamer. This drug is currently in a
phase II/III trial (NCT02686658). Tesidolumab (LFG316,
Novartis, Basel, Switzerland/MorphoSys, Planegg, Ger-
many) is a human monoclonal antibody also targeting C5.
The phase II clinical trial has been completed
(NCT015275000); however, the results have not yet been
published. Currently, another phase II trial is ongoing
which analyzes CLG561 (Novartis, Basel, Switzerland), a
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Fig. 1 Schematic
representation of the
complement system proteolytic
cascade. a Complement-
inhibiting therapies currently
evaluated in clinical trials and
their specific targets are
presented. The targets of the
complement-inhibiting
therapies are complement C3,
complement factor D (FD),
complement C5, properdin and
CD59. C3 is a central
component of the complement
cascade, as upon activation, its
cleavage leads to the formation
of the anaphilatoxin C3a and to
the opsin C3b. C3b will also
form the alternative pathway C3
convertase and all C5
convertases. FD activates the
system through the cleavage of
C3b-bound FB to form the
alternative pathway convertases.
C5 is the second central
component of the cascade
downstream of C3. Upon
cleavage, C5 leads to the
anaphylatoxin C5a and to C5b,
the first component of the
membrane attack complex
(MAC). Properdin is a positive
regulator of the system that
stabilizes the alternative
pathway convertases (C3bBb).
Another inhibitor of the system
acting on the terminal pathway
is MAC-inhibitory protein
(MAC-IP, also known as
CD59), which also recognizes
host cells, and inhibits the
formation of the MAC. A red
line towards the target indicates
inhibition, whereas a green line
indicates augmentation.
C4bC2b and C3(H2O)Bb are C3
convertases; C4bC2bC3b and
C3bBbC3b are C5 convertases.
b Upon activation of the
complement system, C3b is
degraded to C3d on the cell
surface
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fully human antibody Fab that neutralizes properdin, as
monotherapy or in combination with tesidolumab
(NCT02515942). Finally, the first gene therapy tested for
GA treatment is HMR59 (AAVCAGsCD59, Hemera Bio-
sciences Inc., Newton, USA), and its safety is currently
being evaluated in a phase I clinical trial (NCT03144999).
This therapy consists of a single injection of an adeno-
associated virus that transfects the retinal cells, leading to
expression of a soluble form of MAC-inhibitory protein
(MAC-IP, also named CD59). The potential of gene ther-
apies is further described in Sect. 3.2 of this review.
Complement-inhibiting therapies will presumably be
most effective in AMD patients in whom the complement
system is most over-activated. Several studies have eval-
uated levels of complement components and activation
fragments, which may represent useful biomarkers for
treatment response to complement-inhibiting therapies in
AMD. Systemic levels of complement activation fragments
such as Ba, Bb, C3a, C3d and C5a and the C3d/C3 ratio, as
well as levels of complement components FB and FD seem
to be elevated in AMD patients compared to controls
[107–113]. Systemic levels of complement component C3
and FI levels, however, appear not to differ between AMD
patients and controls [108, 109, 111, 113–115]. FH levels
have been reported to be lower in AMD in some studies
[116, 117], but others do not report a difference
[108, 109, 113, 114, 118]. Specific complement levels
could therefore be used to identify AMD patients with high
levels of complement activity. Nevertheless, a high vari-
ability in these complement markers is found within the
AMD and control groups, and the levels show a large
overlap between cases and controls. Consequently, other
markers may be useful as well to predict response. In a
recent study including 31 nvAMD patients and 30 controls,
aqueous humor differences in Ba and C3a levels were
detected, whereas plasma differences were not, probably
due to the limited sample size. These results suggest that
differences in complement activation levels between
patients and controls are larger locally in the eye compared
to systemically [119].
Genetic variants located in or near the CFH, CFI, C9,
C2/CFB, C3 and VNT genes, encoding components of the
complement system, are known to be associated with AMD
[19]. Some of these genetic variants have been shown to
affect complement activation levels, and could therefore
also be used as biomarkers for complement system activity
in AMD. We reviewed the reported associations between
common AMD-associated variants and systemic comple-
ment system levels in Table 2. SNPs rs12144939 and
rs1410996 in the CFH gene have been associated with the
C3d/C3 ratio, and rs800292 has been associated with Ba
and C3d levels and the C3d/C3 ratio [111, 120, 121].
Genetic variants in the C2 and CFB genes have also been
analyzed, and an association with complement activation
fragments has been found for rs4151667 (with C3d/C3, Ba
and FB), rs641153 (with C3d/C3), and rs9332739 (with
Ba) [111, 113, 120, 121]. SNP rs6795735 and rs2230199 in
the C3 gene seem to influence complement system acti-
vation as well. SNP rs6795735 associated with the C3d/C3
ratio, and rs2230199 with levels of C3d, C5a, and the C3d/
C3 ratio [109, 111, 120, 121]. The association of ARMS2
rs10490924 with complement activation is inconclusive.
While one study reported the SNP to influence C5a levels
[109], in another study, it did not [111], and a third study
did not find an association with the C3d/C3 ratio [120]. In a
recent GWAS for complement activation levels, the AMD-
associated variant that showed the strongest effect was
rs6685931 located in the CFHR4 gene. Previous associa-
tions described for CFH and CFB/C2 were confirmed by
the GWAS, while the associations of rs2230199 in C3 and
rs10490924 in ARMS2 could not be confirmed [122].
Recently, rare coding variants in the CFH, CFI, C3 and
C9 genes have been described in AMD patients, and have
also been shown to have an effect on systemic levels of
complement components. Carriers of CFH Arg127His
[123], Arg175Pro [124] and Cys192Phe [125] variants
showed reduced FH levels. In carriers of CFI Gly119Arg
[115], Gly188Ala [115] and Ala240Gly variants [126],
reduced FI levels were observed. Carriers of the C9 variant
Arg95Ter showed C9 levels below the detection level
[127], and in carriers of Pro167Ser [128], C9 levels were
elevated. Other rare variants did not show an effect on
systemic levels individually, but a functional effect on
complement activation has been described. The effect of
these rare variants has been recently reviewed by Geerlings
and colleagues [129]. Rare coding variants, in particular
those showing an effect on complement activation, may
therefore also be useful to select patients for complement-
inhibiting treatments.
Besides genetic biomarkers, other biomarkers that
associate with AMD and complement activity could also be
used to identify AMD patients with an over-activated
complement system. Other reported factors include low
systemic triglyceride levels and high body mass index
(BMI) [120].
3.2 Gene- and Cell-Based Therapies
The high and increasing prevalence of AMD together with
the limited therapeutic options have boosted research for
new therapies [12]. These new therapeutic strategies make
use of the latest technological advances including gene
therapy and stem cells. In this section, we review gene- and
cell-based therapies that have been or are currently being
tested in clinical trials.
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3.2.1 Gene Therapy
Gene therapy introduces specific genetic material into the
patient’s cells, usually by means of a viral vector. The
successful example of gene replacement therapy for the
treatment of a monogenic retinal disease, Leber congenital
amaurosis [130], motivated the development of gene
therapy clinical trials for AMD. In AMD, the focus is on
promoting the expression of a therapeutic protein in RPE
cells. Viral vectors are delivered intravitreally or subreti-
nally. An overview of gene therapy clinical trials for AMD
is presented in Table 3.
AAVCAGsCD59, discussed in Sect. 3.1, is the only
gene therapy trial targeting the complement system which
is currently being tested for GA, and inhibits MAC for-
mation through CD59 expression. Other gene therapy trials
target the neovascular form of AMD. AdGVPEDF.11D
leads to expression of pigment epithelium-derived fac-
tor (PEDF), an anti-angiogenic protein that counteracts the
effects of VEGF in the CNV process [131]. This therapy
has not been further evaluated since the results of the phase
I trial in 2006 [132]. AAV2-sFLT01 and rAAV.sFLT-1
both express soluble vascular endothelial growth factor
receptor 1 (sFLT-1), an antagonist for VEGF [133]. The
results of the phase I trial of AAV2-sFLT01 have recently
been published with positive safety data and toleration of
the drug after 3 years [134]. rAAV.sFLT-1 has already
been evaluated in phase IIa; however, the control and the
Table 2 AMD SNPs associated with systemic levels of complement components
Gene SNP Study Allele/genotype
tested
Complement activation
measurement(s)
Direction of the
effect
P value
CFH rs12144939 Ristau et al. [120] T C3d/C3 - 4.6 9 10-6
rs1410996 Ristau et al. [120] T C3d/C3 - 10-4
Reynolds et al. [109] TT, CT and TT Bb, C3a, C5a, FH NA
rs800292 Hecker et al. [111] G Ba ? 7.1 9 10-6
Hecker et al. [111] G C3d ? 0.0013
Ristau et al. [120] A C3d/C3 - 0.003
Paun et al. [121] A C3d/C3 - 0.002
Hecker et al. [111] G FB, FD, FH/FHR-1 NA
CHFR4 rs6685931 Lores-Motta et al.
[122]
C C3d/C3 ? 6.32 9 10-8
CFB rs4151667 Hecker et al. [111] T Ba ? 3.9 9 10-6
Ristau et al. [120] A C3d/C3 - 1.0 9 10-5
Paun et al. [121] A C3d/C3 - 4.1 9 10-6
Hecker et al. [111] T FB, FD, FH/FHR-1, C5a, C3d NA
Smailhodzic et al.
[113]
TA FB - \0.001
rs641153 Paun et al. [121] A C3d/C3 - 0.048
Reynolds et al. [109] CT/TT Bb, C3a, C5a, FH NA
C2 rs9332739 Hecker et al. [111] G Ba ? 2 9 10-6
Hecker et al. [111] G FB, FD, FH/FHR-1, C5a, C3d NA
Reynolds et al. [109] CG/CC Bb, C3a, C5a, FH NA
C3 rs6795735 Ristau et al. [120] A C3d/C3 ? 0.04
rs2230199 Reynolds et al. [109] CG/GG C5a ? 0.04
Ristau et al. [120] G C3d/C3 ? 0.04
Paun et al. [121] G C3d/C3 ? 0.035
Hecker et al. [111] C C3d ? 0.039
Hecker et al. [111] C FB, FD, FH/FHR-1, C5a, Ba NA
Reynolds et al. [109] CG/GG Bb, C3a, FH NA
ARMS2 rs10490924 Reynolds et al. [109] GT/TT C5a ? 0.02
Reynolds et al. [109] GT/TT Bb, C3a, FH NA
Hecker et al. [111] NS FB, FD, FH/FHR-1, C5a, Ba, C3d NA
AMD age-related macular degeneration, NA not associated, NS not specified, SNP single-nucleotide polymorphism
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treatment groups performed worse than ranibizumab alone
group [135]. OXB-201, also known as RetinoStat, leads to
the expression of the anti-angiogenic proteolytic products
angiostatin and endostatin [136, 137]. Phase I has already
been completed, and no adverse events were observed
[138]; therefore, long-term safety studies are ongoing.
Finally, RGX-314 encodes for a soluble anti-VEGF protein
and is currently being evaluated in phase I clinical trials.
Anti-angiogenic factors delivered using gene therapy
might show also a variability in response as it has been
described for the currently used anti-VEGF antibodies.
Therefore, pharmacogenetic associations found for anti-
VEGF therapy might be analyzed in clinical trials of gene
therapy for nvAMD.
In addition, research on gene therapy for supplementa-
tion of FH is currently ongoing [139], and supplementation
therapy for FI might be useful, as carriers of rare variants
show reduced FI levels. For this particular therapy, patient
selection based on genotype will be required. Carriers of
rare variants in CFH and CFI known to have strong effects
on the protein function or levels would be the best candi-
dates for inclusion in clinical trials.
3.2.2 Stem Cell Therapy
Another novel therapeutic approach with great potential for
AMD is the use of stem cells, which are reprogrammed to
the cell type of interest and transplanted to the patient.
Transplantation of RPE cells derived from stem cells for
AMD treatment is currently being evaluated in several
clinical trials (Table 3). The first clinical trial started in
2011 and involved human embryonic stem cell (hESC)-
derived RPE cells (NCT01344993). The therapy was found
to be safe with no tumorigenicity and showed potential
effectiveness [140, 141]. These results have been followed
up with a new improved therapy (NCT03178149,
NCT03167203) that is currently being evaluated by
developers in the Astellas Institute for Regenerative Med-
icine. Other ongoing clinical trials are also based on hESC-
derived RPE; however, their use requires immunosup-
pressive treatment, bearing risks [142] and raising ethical
concerns due to the use of embryonic cells. More recently,
the use of induced pluripotent stem cells (iPSC) has begun
to be explored. One of the key benefits of this therapy is
that immunosuppression is not needed, as the source is the
patient’s own somatic cells. However, it implies an
increased cost of therapy, as it needs to be developed for
each patient individually. The first clinical trial with iPSC
(http://www.umin.ac.jp, UMIN000011929) has recently
been performed at the Japanese research institute RIKEN,
where a 70-year-old AMD patient received a transplant of a
sheet of autologous iPSC-RPE. After 1 year of follow-up,
no adverse events had been detected and the patient’sT
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vision remained stable [143]. However, this trial has been
stopped for the second patient enrolled, because of genetic
changes found in the generated iPSC [144]. This group has
recently shifted their approach towards the use of allogenic
human leukocyte antigen (HLA)-matched iPSC-RPE, and
in March 2017, it was announced that the first patient
received allogenic iPSC-RPE [145]. This approach would
be less costly and would avoid the effect of the genetic
AMD-risk variants that the patients carry. Nevertheless, it
would most likely imply the use of immunosuppressant
drugs. Contrary to these promising results of the group in
RIKEN, in a back-to-back publication, it was reported that
autologous adipose tissue-derived stem cells were admin-
istered bilaterally to three AMD patients in a stem cell
clinic, leading to a severe visual loss in all cases [146].
These disastrous events highlight that even though stem
cell therapy holds promise, strict regulations should be
applied before any treatment with stem cells is adminis-
tered to patients.
RPE stem cell therapy might be the best therapeutic
option for advanced cases in which there is RPE degen-
eration; however, it involves the transplantation of new
cells in a diseased environment, and as such, the survival of
the new cells may depend on inflammation and oxidative
stress levels in the host environment. The C3/C3 ratio, as a
marker of complement activation, malondialdehyde levels,
as a marker of lipid peroxidation, and homocysteine levels,
an oxidative stress marker, are molecular biomarkers for
AMD that may correlate with the success of such therapies
[147]. Moreover, autologous iPSC might not be the best
option for AMD patients carrying highly penetrant genetic
variants, and hESC or HLA-matched iPSC may be more
effective in these patients.
4 Discussion and Future Perspectives
The use of genetic biomarkers to advise patients with AMD
on the use of dietary supplements is a topic of intense
debate that has not yet been settled. Based on the recent
findings of Assel at al. [35], dietary supplementation for
slowing down disease progression should be prescribed to
any AMD patient, irrespective of CFH and ARMS2 geno-
types, but this is contradicted by a more recent study by
Vavvas et al. on an extended dataset, which concluded that
the use of the AREDS formulation should be based on
patient-specific genotypes [36]. However, the findings in
all studies of this debate are based on the AREDS dataset
only, and future independent prospective studies would be
beneficial to draw a definite conclusion, as well as to fur-
ther investigate if other genetic variants may interact with
the formulation.
In regard to the pharmacogenetics of anti-VEGF treat-
ment, results are not conclusive yet; therefore, these results
are not yet helpful for precision medicine. Nonetheless,
recurrent results from multiple studies suggest that SNP
rs1061170 in CFH may influence response to treatment.
This finding could potentially be explained by the effect of
this SNP on faster disease progression [148]. However, this
association was not detected in the analyses from the
CATT and IVAN clinical trials [71, 72], therefore war-
ranting further investigation. Additionally, the magnitude
of the effect of this variant might not reach clinical utility
and would need to be combined with other genetic variants
or clinical parameters. Other compelling candidate genetic
variants for further evaluation include ARMS2 rs10490924,
VEGFA rs833061, OR52B4 rs4910623, NRP1 rs2070296,
APOE e4 allele, IL8 rs4073 and PEDF rs1136287. OR52B4
rs4910623 was identified in a GWAS using pooled DNA,
indicating that a GWAS with single-patient genotyping and
increased statistical power may reveal new associated
variants. Additionally, rare variants potentially bearing
larger effects, and therefore clinical relevance, have not
been evaluated yet [149].
A key problem remains that the definition of response is
not consistently defined across cohorts. In 2015, in order to
provide a consensus, a committee of retinal specialists
proposed definitions of good, poor and non-response based
on a combination of anatomical and functional measure-
ments [150]. These definitions should be adopted by
researchers in future studies, which would enable study
comparisons in a standardized framework. Analysis of the
different outcome measures used for these definitions as
continuous variables would be also highly valuable.
Additionally, prospective studies with sufficient statistical
power would allow sub-phenotype analyses, which may
reveal new or stronger associations.
Biomarkers identified in aqueous humor samples are
VEGF and IL-6; however, these samples are not taken
routinely. IL-6, IL-17, TNF-a and C3a have been identified
as potential systemic biomarkers, and therefore could be
readily measured before treatment. Moreover, as baseline
VEGF has been associated with response in aqueous humor
samples, it could be further investigated as a systemic
biomarker. Recent studies suggest that anti-VEGF treat-
ment may lead to an increased risk of GA development
[151]. Therefore, screening of genetic markers together
with other biomarkers and clinical parameters for effective
anti-VEGF therapy planning may become necessary.
Clinical trials would be albeit needed before the screening
of these biomarkers can be implemented in the clinic.
Complement therapies are being developed for the
treatment of GA, and biomarkers for complement activity
could be useful to identify the most suitable AMD patients
for these therapies. Systemic levels of complement
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activation fragments such as the C3d/C3 ratio can be used
as biomarkers for complement activity in AMD. Moreover,
levels of the specific target of each drug could be a useful
biomarker. Therapies undergoing trials are targeting FD,
C3, properdin and C5. FD levels have been seen to be
higher in AMD patients compared to controls, and there-
fore, they could be a useful biomarker for this specific
therapy. C3 levels do not differ between AMD and con-
trols, and properdin and C5 levels have not been evaluated.
A comprehensive analysis of the complement system
components in AMD could identify new potential
biomarkers. However, how systemic measurements reflect
the local situation at the disease site needs to be further
investigated.
Additionally, AMD-associated SNPs that associate with
systemic complement activation can be used as robust
biomarkers. The added value of these genetic biomarkers is
that as they are associated with disease risk, they most
probably reflect complement activity in the eye, whereas
the overall systemic complement activation may not
always be representative of the conditions at the disease
site. rs12144939, rs1410996 and rs800292 in CFH,
rs4151667, rs641153 and rs9332739 in C2/CFB, and
rs6795735 and rs2230199 in C3 have been reported to be
associated with systemic complement activation levels. In
a recent GWAS for complement activation levels, the
AMD-associated variant that showed the strongest effect
was rs6685931 located in the CFHR4 gene. Moreover, rare
variants in the CFH gene (Arg127His, Arg175Pro and
Cys192Phe), in the CFI gene (Gly119Arg, Gly188Ala and
Ala240Gly) and in the C9 gene (Arg95Ter and Pro167Ser)
have been associated with altered FH, FI and C9 levels,
respectively. However, the magnitude of the effects of
these genetic variants at the disease site still needs to be
evaluated. Additionally, other variants for which a sys-
temic effect has not been detected most probably have a
local effect. Consequently, genetic studies using aqueous
humor samples are greatly needed. The identified genetic
factors may be used alongside systemic complement acti-
vation levels and other environmental factors such as BMI
and triglyceride levels to identify AMD patients with a
burden of the complement system in their AMD disease.
Well-powered replication studies are needed, as well as
comprehensive genetic studies of the effect of all the 52
independently AMD-associated variants on systemic
complement activation levels [19].
Other new therapeutic approaches will most probably
not work in the same manner for all AMD patients. As a
consequence, a deeper molecular characterization of AMD
patients including proteomics, metabolomics, transcrip-
tomics and genomics is essential. Such in-depth charac-
terization will help to understand the molecular drivers in
each individual patient and to develop pharmacomics,
paving the way towards precision medicine in AMD.
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